Abpro Holdings (ABPO) Interest Expenses (2022 - 2026)
Abpro Holdings' (ABPO) quarterly Interest Expenses came in at $72000.0 in Q1 2026, down 90.23% YoY from $737000.0 in Q1 2025, and up 41.18% on a QoQ basis from $51000.0 in Q4 2025.
Abpro Holdings (ABPO) Interest Expenses (2022 - 2026) Analysis & Trends
Abpro Holdings (ABPO) has 5 years of Interest Expenses data on file, last reported at $72000.0 in Q1 2026.
- Quarterly Interest Expenses fell 90.23% year-over-year to $72000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $511000.0 (down 60.33% YoY) and the FY2025 annual result came in at $33.7 million, up 1.26% from the prior year.
- Interest Expenses grew to $72000.0 in Q1 2026, from $51000.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $737000.0 in Q1 2025 to a low of -$104646.0 in Q4 2023.
- A 5-year average of $187714.6 and a median of $145823.0 in 2023 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2023 — Interest Expenses slumped 126.93% — and 2025, when it soared 1654.76%.
- Tracing ABPO's Interest Expenses over 5 years: stood at $388575.0 in 2022, then tumbled by 126.93% to -$104646.0 in 2023, then surged by 373.3% to $286000.0 in 2024, then slumped by 82.17% to $51000.0 in 2025, then soared by 41.18% to $72000.0 in 2026.
- The last three Interest Expenses figures came in at $72000.0 (Q1 2026), $51000.0 (Q4 2025), and $214000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Abpro Holdings | 1.14 Mn | 1.14 Mn | - | 23,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 72,000.00 |
| Mar 31, 2026 | 72,000.00 |
| Dec 31, 2025 | 51,000.00 |
| Dec 31, 2025 | 51,000.00 |
| Sep 30, 2025 | 214,000.00 |
| Sep 30, 2025 | 214,000.00 |
| Jun 30, 2025 | 174,000.00 |
| Jun 30, 2025 | 174,000.00 |
| Mar 31, 2025 | 737,000.00 |
| Mar 31, 2025 | 737,000.00 |
| Dec 31, 2024 | 286,000.00 |
| Dec 31, 2024 | 286,000.00 |
| Sep 30, 2024 | 164,000.00 |
| Sep 30, 2024 | 164,000.00 |
| Jun 30, 2024 | 101,000.00 |
| Jun 30, 2024 | 101,000.00 |
| Mar 31, 2024 | 42,000.00 |
| Mar 31, 2024 | 42,000.00 |
| Dec 31, 2023 | -104,646.00 |
| Dec 31, 2023 | -104,646.00 |